He Shi-yang, Li Jun. Research advances of calcium dobesilate in the treatment of renal fibrosis[J]. Journal of Clinical Nephrology, 2023, 23(9): 774-778. DOI: 10.3969/j.issn.1671-2390.2023.09.012
    Citation: He Shi-yang, Li Jun. Research advances of calcium dobesilate in the treatment of renal fibrosis[J]. Journal of Clinical Nephrology, 2023, 23(9): 774-778. DOI: 10.3969/j.issn.1671-2390.2023.09.012

    Research advances of calcium dobesilate in the treatment of renal fibrosis

    • Renal fibrosis is a common pathological manifestation of most renal diseases. Formation of inflammatory microenvironment plays an important role in the progression of renal fibrosis. Intervention measures for early inflammation are vital for proper clinical managements of renal fibrosis. With anti-inflammatory and anti-oxidative stress properties, calcium dobesilate is a proven vasoprotective drug of protecting endothelial cells and improving microcirculation. It is mainly indicated for diabetic retinopathy. In recent years, the application of calcium dobesilate has been gradually expanded to managing diabetic nephropathy and obstructive nephropathy. This review summarized the latest researches of calcium dobesilate in the treatment of renal fibrosis.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return